FDA Drug Safety Podcasts
Avsnitt

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)

FDA Drug Safety Podcasts
Dela

Listen to an audio podcast of the June 30, 2022, FDA Drug Safety Communication. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib) compared to another medicine to treat leukemia and lymphoma.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Innehållet i podden är skapat av U.S. Food and Drug Administration, Center for Drug Evaluation and Research och inte av, eller tillsammans med, Poddtoppen.